dihexa solution stability data | 1401708-83-5 | BGC70883 Dihexa | | 1401708-83-5 |

A Turning Point, But Not a Final Decision Despite the momentum suggested by this update, important limitations remain

D-Retro-Inverso (DRI) Technology FOXO4-DRI utilizes a specialized D-retro-inverso peptide design

Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions

It represents a precautionary approach given limited long-term data rather than a response to documented concerns

Rat inferior caval vein (ICV) ligature and particular pentadecapeptide BPC 157 action

Sikiric P, Seiwerth S, Mise S, et al